Moderna amends credit agreement, cuts loan margins and extends maturity
The company lowered interest rate margins on its term loans by 0.75 percentage points and pushed the maturity date out one year to November 2031.
Moderna, Inc. entered into an amendment to its existing Credit and Guaranty Agreement on November 9, 2026, according to a Form 8-K filed with the SEC. The amendment modifies the company's Credit and Guaranty Agreement originally dated November 19, 2025, which involves Moderna as borrower, guarantor subsidiaries, a group of lenders, and Ares Capital Corporation acting as administrative agent and collateral agent.1 Moderna, Ares Capital Corporation, and the lenders entered into the amendment, which took effect on November 9, 2026.1
The amendment reduces the applicable interest rate margins for the initial term loans and delayed draw term loans by 0.75 percentage points, from 5.50% to 4.75% per annum for loans bearing interest at a forward-looking term rate derived from the Secured Overnight Funding Rate and from 4.50% to 3.75% per annum for loans bearing interest based on the base rate.1 It also extends the maturity date for those loans from November 24, 2030 to November 24, 2031.1
On the delayed draw term loan commitments, the amendment extends the availability period for the first $400 million from November 24, 2027 to November 24, 2029, and for the remaining $500 million from November 24, 2028 to November 24, 2029, in each case subject to earlier termination under the credit agreement.1 Any future borrowings of delayed draw term loans remain subject to the conditions set out in the credit agreement.1
Apart from the changes made by the amendment, the underlying credit agreement continues in effect, including its guarantee and collateral security provisions.1 The filing was signed by Chief Financial Officer James M. Mock and dated November 16, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.